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ABSTRACT 
 
Background: Parkinson’s disease is a progressive neurodegenerative disorder that results in 
the widespread loss of select classes of neurons throughout the nervous system. The 
pathological hallmarks of Parkinson’s disease are Lewy bodies and neurites, of which α-
synuclein fibrils are the major component. α-Synuclein aggregation has been reported in the 
gut of Parkinson’s disease patients, even up to a decade before motor symptoms, and similar 
observations have been made in animal models of disease. However, unlike the central 
nervous system, the nature of α-synuclein species that form these aggregates and the classes 
of neurons affected in the gut are unclear. We have previously reported selective expression 
of α-synuclein in cholinergic neurons in the gut (1), suggesting they may be particularly 
vulnerable to degeneration in Parkinson’s disease.  
Methods: In this study, we used immunohistochemistry to detect α-synuclein oligomers and 
fibrils via conformation-specific antibodies after rotenone treatment or prolonged exposure to 
high [K+] in ex vivo segments of guinea-pig ileum maintained in organotypic culture.  
Key Results: Rotenone and prolonged raising of [K+] caused accumulation of α-synuclein 
fibrils in the axons of cholinergic enteric neurons. This took place in a time- and, in the case 
of rotenone, concentration-dependent manner. Rotenone also caused selective necrosis, 
indicated by increased cellular autofluorescence, of cholinergic enteric neurons, labeled by 
ChAT-immunoreactivity, also in a concentration-dependent manner.  
Conclusions & Inferences: To our knowledge, this is the first report of rotenone causing 
selective loss of a neurochemical class in the enteric nervous system. Cholinergic enteric 
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neurons may be particularly susceptible to Lewy pathology and degeneration in Parkinson’s 
disease. 
 
KEY MESSAGES 
• Constipation is a common complaint in Parkinson’s disease. Selective neuronal 
vulnerability is a hallmark of the disease; however, whether select classes of enteric 
neurons are particularly vulnerable to degeneration in the disease is unclear. 
 
• Here, we show that rotenone, a pesticide implicated in Parkinson’s disease, and 
elevated potassium cause accumulation of α-synuclein, a key feature of Parkinson’s 
disease, in cholinergic enteric neurons. 
 
• Enteric cholinergic neurons may be particularly vulnerable to degeneration in 
Parkinson’s disease, which may underlie constipation.  
 
INTRODUCTION 
 
Parkinson’s disease is a progressive neurodegenerative disorder characterized by the 
widespread loss of select classes of neurons throughout the nervous system. The pathological 
hallmarks of sporadic Parkinson’s disease are Lewy bodies and neurites: abnormal protein 
aggregates found in surviving nerve cell bodies and axons at sites of neurodegeneration, of 
which the presynaptic protein, α-synuclein, is the major constituent (2, 3, 4). Many structures 
outside of the substantia nigra pars compacta (SNpc) are damaged by the disease (5) and there 
is now strong evidence that sporadic Parkinson’s disease starts at a remote site before 
spreading to the SNpc (6, 7). Putative sites of initiation are regions in the periphery connected 
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to the brainstem, including the olfactory mucosa and gastrointestinal (GI) tract (8). 
Although Parkinson’s disease is best known for its characteristic motor symptoms, non-
motor symptoms impose a significant burden on quality of life (10, 11). These arise early 
in the course of disease and are often unresponsive to, or worsened by, dopamine-
replacement therapy (11, 12). The dominance of non-motor symptoms in the pre-clinical 
stages of disease has helped guide the quest for biomarkers that can provide an accurate 
diagnosis before the onset of motor symptoms. For this reason, much attention has been 
focused on the GI tract, which is heavily burdened by Lewy pathology (13) and 
commonly expresses symptoms including dysphagia, bloating and constipation (14). Of 
these, constipation has been reported to manifest as early as 10 years prior to motor 
symptoms (15). Curiously, accumulation of α-synuclein can occur in the gut up to 10 years 
prior to diagnosis (16). The gut’s putative role in the pathogenesis of Parkinson’s disease 
and its accessibility makes it suitable for investigating mechanisms underlying disease 
pathogenesis and assessing efficacy of disease-modifying agents and candidate disease 
biomarkers. Aggregation of α-synuclein is central to these goals. Mutations in SNCA, the 
gene encoding α-synuclein, as well as gene duplications and triplications, which increase 
its propensity to aggregate, can cause Parkinson’s disease (17). α-Synuclein oligomers are 
elevated in the cerebrospinal fluid in Parkinson’s disease (18,19) and can seed the 
aggregation of endogenous α-synuclein in both central (20) and peripheral (21, 22) 
neurons. Although the mechanisms are not entirely clear, mitochondrial dysfunction and 
oxidative stress may contribute to aggregation of α-synuclein in Parkinson’s disease (23). 
There is a positive relationship between exposure to the pesticide rotenone and risk of 
Parkinson’s disease (24), and biochemical studies implicate a systemic defect in 
mitochondrial complex I (25). Rotenone is a mitochondrial complex I inhibitor capable of 
replicating the classic features of Parkinson’s disease, thereby demonstrating a direct link 
between mitochondrial dysfunction and α-synuclein aggregation (26, 27). Metabolic stress 
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evoked by elevated intracellular calcium concentration provoked by raised extracellular 
potassium concentration can also induce α-synuclein aggregation (28). Accordingly, the 
disease selectively targets highly metabolically active populations of neurons, but spares 
those that express high levels of calcium binding proteins (29).  
In this study, we used immunohistochemistry to determine whether rotenone or prolonged 
exposure to raised [K+] in organotypic culture triggers accumulation of α-synuclein in the cell 
bodies and axons of enteric neurons in the guinea-pig ileum. We used a conventional antibody 
against α-synuclein in addition to novel conformation-specific antibodies against α-synuclein 
oligomers and fibrils (30). 
MATERIALS AND METHODS 
Guinea-pig tissue collection 
Adult guinea-pigs of either sex (weight 230–400g) were stunned and killed by 
exsanguination, in a manner approved by the Animal Welfare Committee of Flinders 
University, South Australia. Animals were opened along the ventral midline and the ileum 
with mesentery attached was removed, intestinal contents were flushed and the preparation 
placed in Krebs solution (118mM NaCl, 4.75 mM KCl, 1.0mM NaH2PO4, 25 mM NaHCO3, 
1.2mM MgSO4, 11.1 mM D-glucose, 2.5mM CaCl2, bubbled with 95%O2/5%CO2). Tissue 
was pinned in a Sylgard-lined Petri dish (Dow Corning, Midland, MI) and the gut was opened 
longitudinally alongside the mesenteric border. The mucosa and submucosa were carefully 
removed via sharp dissection and discarded and the remaining preparation was pinned circular 
muscle-side up. Krebs solution was changed regularly during dissection.  
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Organotypic culture 
Tissue was kept alive in an organotypic culture in medium [Dulbecco’s modified 
Eagle’s/Ham’s F12, Sigma (1: 1 ratio mix, supplemented with L-glutamine and 
15 mmol L−1 hydroxyethyl piperazineethanesulfonic acid (HEPES))]; including 10% fetal 
bovine serum, 1.8 mmol L−1 CaCl2, 100 IU mL−1 penicillin, 100 μg mL−1 streptomycin D, 
2.5 μg mL−1 amphotericin B, 20 g mL−1 gentamycin, Cytosystems, Castle Hill, Australia) for 
either 1, 2 or 4 days of culture. Rotenone was prepared in 100% DMSO as 0.1M solution and 
KCl was prepared as a 1M stock in distilled water. Tissue was maintained in organotypic 
culture in one of four serum-supplemented DME/F12 solutions containing: 10μM rotenone 
(final DMSO concentration of 0.01%); 1μM rotenone (final DMSO concentration of 0.001%); 
10mM KCl; and standard medium (final DMSO concentration of 0.01%). Previous studies 
have demonstrated that DMSO concentrations at and below those used in the present study 
lack pharmacological activity (31). In addition, a specimen of tissue was taken from each 
animal immediately after euthanasia, maximally stretched and fixed immediately in modified 
Zamboni’s fixative (2% formaldehyde, 15% saturated picric acid in 0.1M phosphate buffer, 
pH 7.0) for approximately 24 hours at 4°C. After 1, 2 or 4 days in culture, preparations were 
maximally stretched and fixed as above. Tissue was then cleared with three washes of 100% 
dimethylsulphoxide (DMSO), and stored in PBS at 4°C. For immunohistochemical labeling 
of myenteric ganglia, the circular muscle layer was removed by sharp dissection prior to 
incubation in antisera. 
Immunohistochemistry 
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Preparations of myenteric plexus and longitudinal muscle, or strips of circular muscle, were 
cut into pieces approximately 10mm x 10mm and incubated with antisera against different 
combinations of markers (Table 1) at room temperature for two days. Preparations were 
rinsed three times in PBS and incubated with secondary antisera (Table 2) for 4 hours at room 
temperature. After a final rinse with PBS, preparations were equilibrated with 50%, 70%, and 
100% carbonate-buffered glycerol, and mounted in 100% carbonate-buffered glycerol (pH 
8.6). All antibodies were diluted in 0.1 M PBS (0.3 M NaCl) containing 0.1% sodium azide. 
Controls for double-labeling were performed by omitting one or more primary antibodies 
from the procedure, and by ensuring that all combinations of primary and secondary antisera 
were free of cross-reactivity. 
Antibody characterisation 
Syn-O1 
The Syn-O1 antibody was a monoclonal raised in mice against α-synuclein fibrils (30). The 
antibody selectively binds α-synuclein oligomers and fibrils and not α-synuclein monomers 
on inhibition ELISA and dot blotting (30). When α-synuclein oligomers, protofibrils and 
fibrils were blotted on a nitrocellulose membrane, Syn-O1 detected all three conformations, 
but showed greatest immunoreactivity for fibrillar α-synuclein (30). Preabsorption of Syn-O1 
with α-synuclein fibrils completely abolished its ability to detect α-synuclein fibrils, whereas 
preabsorption with α-synuclein monomers had little effect on its immunoreactivity (30). On a 
nitrocellulose membrane, the Syn-O1 antibody did not recognize monomers or fibrils 
generated from β- or γ-synuclein, or the fibrillar forms of other amyloidogenic proteins 
including Aβ, Tau40, IAPP or ABri (30).  
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Syn-F2 
The Syn-F2 antibody was a monoclonal raised in mice against α-synuclein fibrils (30). The 
antibody selectively binds α-synuclein fibrils and not α-synuclein monomers on inhibition 
ELISA and dot blotting (30). When α-synuclein oligomers, protofibrils and fibrils were 
blotted on a nitrocellulose membrane, Syn-F2 did not detect oligomers, had low 
immunoreactivity for protofibrils, but showed strong immunoreactivity for fibrillar α-
synuclein (30). Preabsorption of Syn-F2 with α-synuclein fibrils completely abolished its 
ability to detect α-synuclein fibrils, whereas preabsorption with α-synuclein monomers had 
little effect on its immunoreactivity (30). On a nitrocellulose membrane, the Syn-F2 antibody 
did not recognize monomers or the fibrils generated from β- or γ-synuclein, or the fibrillar 
forms of other amyloidogenic proteins including Aβ, Tau40, IAPP or ABri (30).  
Microscopy, image analysis and processing 
Specimens of fresh-fixed and organ-cultured tissue cultured were examined on an Olympus 
IX71 microscope (Japan) equipped with epifluorescence and highly discriminating filters 
(Chroma Technology Co., Battledore, VT). Images were captured using a Roper scientific 
(Coolsnap) camera at 1392 x 1080 pixels, using AnalySIS Imager 5.0 (Olympus-SIS, 
Münster, Germany) and saved as TIFF files. Micrographs of autofluorescent and 
immunohistochemically-labeled nerve structures were captured using a 40x objective water-
immersion lens and displayed in ImageJ (NIH, Bethesda, MD). The identify of the 
preparations was concealed from the microscopist prior to analysis and several sampling 
techniques were utilized.  
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We quantified nerve cell bodies and abnormally large varicosities labeled by the conventional 
antibody against α-synuclein as follows. Images were taken of 30 randomly selected areas of 
tertiary plexus and 20 randomly selected myenteric ganglia by blindly moving the microscope 
stage to a new randomly selected area on the slide, then imaging the closest myenteric 
ganglion or area of tertiary plexus. The coordinates of each image were recorded to ensure the 
same area was never imaged twice. The number of cell bodies and abnormally large 
varicosities in each image were then counted. Totals were obtained in each of four guinea-
pigs. The same methodology was used to obtain images of myenteric ganglia and tertiary 
plexus and to quantify the number of neural structures labeled with antisera against α-
synuclein oligomers or α-synuclein fibrils.  
In preparations that had not been labeled with antisera, dim, autofluorescent nerve cell bodies 
could be detected under all filter combinations (AMCA, FITC, Cy3 and Cy5). However, these 
were most prominent under the FITC filter set. When these preparations were subsequently 
labeled with antisera for ChAT (Cy5 fluorophore) and NOS (Cy3 fluorophore), this 
autofluorescence could no longer be detected in either Cy3 or Cy5 channels, presumable 
because labeling increased the background and swamped the dim autofluorescent signal. 
However, the autofluorescence remained visible in the FITC channel. This made it possible to 
determine the presence of ChAT- and NOS-immunoreactivity in autofluorescent nerve cell 
bodies.  
Data collected from varicosity and cell body counts were rescaled for each animal using the 
following equation: x’ = x – min (x) / max (x) – min (x), where x’ is the normalised value, x is 
the original count, min (x) is the minimum value counted for that animal, and max (x) is the 
maximum value counted for that animal. The mean number of cell bodies or varicosities 
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immunoreactive for a particular marker was calculated by generating an average of the 
normalised counts generated from each of the four animals. Group data were expressed as 
percentage means ± standard error of the mean (SEM), with n referring to the number of 
animals. The average total number of  autofluorescent cell bodies was expressed as the mean 
of the total number of cells ± SEM, with n referring to the number of animals.  
Fluorescence micrographs were prepared with Adobe Photoshop CS5 (San Jose, CA). Figures 
were generated from grayscale images adjusted for contrast and brightness and were cropped 
and resized, but no other digital processing was used. 
Statistical analysis 
One-way analysis of variance (ANOVA) with Tukey's HSD Test in SPSS19 for PC (SPSS, 
Chicago, IL) was used to compare the means of more than two samples. The means of two 
samples were compared by a Student's unpaired t-test in Microsoft Excel 2008 for Mac 
(Microsoft, Santa Rosa, CA).  Differences were considered significant at P < 0.05. 
RESULTS 
Accumulation of α-synuclein in axons and cell bodies during organotypic culture 
The tertiary plexus contains the axons of inhibitory nitrergic motorneurons and more 
abundant excitatory cholinergic motorneurons, which supply the overlying longitudinal 
muscle layers. Previous studies have shown that α-synuclein is expressed in the axons of all 
cholinergic motorneurons, identifiable by immunoreactivity for vesicular acetylcholine 
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transporter (VAChT), and is not expressed in the axons of nitrergic motorneurons, identified 
by immunoreactivity for NOS (33). 
When guinea-pig ileum was maintained in organ culture, abnormally large varicosities were 
visible in the tertiary plexus after immunolabeling with the conventional antibody against α-
synuclein (Figure 1). On average, their surface area was seven times greater than that of 
randomly sampled normal varicosities (Table 3). An observer, blinded to the tissue treatment, 
quantified these abnormally large varicosities in the tertiary plexus that were labeled by the 
conventional α-synuclein antibody from preparations cultured in each of the four solutions 
(Table 4). Total numbers of abnormally large α-synuclein varicosities varied considerably but 
they were consistently absent in all preparations that were fixed immediately after removal 
from the animal. Large varicosities were seen in all preparations subjected to organ culture, 
including those in standard DME/F12 medium without either rotenone or KCl. In most cases, 
large varicosities appeared by day 1, reached peak numbers by day 2, and reduced again by 
day 4 (Table 4). With 10μM rotenone, the peak number of large varicosities in the tertiary 
plexus appeared at day 4, but this did not reach significance (P > 0.05 in all instances, f = 
2.624, df = 11). Similar abnormally large α-synuclein varicosities were also visible in the 
circular muscle and probably in the myenteric plexus, but could not be quantified for 
technical reasons. This suggests that the process of maintaining tissue in organ culture causes 
a small subset of varicosities to swell significantly, and this was not significantly affected by 
either rotenone or raised KCl. 
Using the same conventional antibody to α-synuclein, we have previously reported that α-
synuclein-immunoreactivity is not detectable in myenteric nerve cell bodies of the guinea-pig 
ileum fixed immediately after removal from the animal (33), although it is abundant in axons. 
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This was confirmed in the present study and extended by the observation that no detectable 
accumulation of α-synuclein was detectable in enteric nerve cell bodies after 1-4 days of 
organ culture in standard medium, 1μM or 10μM rotenone, or in medium supplemented with 
10mM KCl.  
 
Characterisation of antibodies against α-synuclein oligomers and fibrils 
 
Aggregation of α-synuclein in nerve terminals and cell bodies is strongly implicated in the 
pathogenesis of Parkinson’s disease. We used novel conformation-specific antibodies against 
α-synuclein fibrils and oligomers to detect these species in guinea-pig myenteric neurons after 
organotypic culture with and without rotenone and KCl (30). Control preparations of 
myenteric plexus were fixed immediately after removal from the animal and then processed 
for immunohistochemistry with a range of concentrations of antisera to α-synuclein fibrils 
(Syn-F2) and α-synuclein oligomers (Syn-O1). Both antibodies produced labeling of 
varicosities in myenteric ganglia, internodal strands, circular muscle plexus and tertiary 
plexus, but did not label enteric nerve cell bodies or inter-varicose fibres (Figure 2). This 
pattern was identical to previous reports using the conventional antibody to α-synuclein (29). 
We then identified a dilution threshold, below which labeling of varicosities in fresh-fixed 
tissue disappeared. The threshold dilution for these antibodies was: Syn-F2 (1:200) and Syn-
O1 (1:1500). These threshold dilutions were then used to identify whether expression levels 
of their specific antigens (oligomers or fibrils) had increased above baseline under different 
conditions of organotypic culture. 
 
Accumulation of α-synuclein fibrils in axons during organotypic culture 
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α-Synuclein fibrils could not be detected in axons or cell bodies in the myenteric plexus, 
tertiary plexus or circular muscle plexus in fresh-fixed preparations, using the threshold 
concentration of 1:200. Nor was labeling detectable after 1 and 2 days culture in standard 
DME/F12 medium (Figure 3). After 4 days of culture very weak and diffuse labeling was 
detected in the tertiary plexus in 1 of 4 preparations (Figure 3). In contrast, in DME/F12 with 
1μM rotenone (Figure 4), 10μM rotenone (Figure 5), or 10mM KCl (Figure 6), α-synuclein 
fibrils could be readily detected in axons in the myenteric plexus, tertiary plexus and circular 
muscle plexus in 4 out of 4 preparations at 1, 2 and 4 days. In the first 2 days, α-synuclein 
fibrils were more abundant in the tertiary plexus than in the myenteric plexus, but by 4 days 
this difference had disappeared (Figures 4, 5 and 6). No accumulation of α-synuclein fibrils in 
myenteric nerve cell bodies was detected under any of the conditions tested.  
 
Accumulation of α-synuclein oligomers in axons during organotypic culture 
 
After 1, 2 or 4 days of culture, α-synuclein oligomers could not be detected in axons in the 
myenteric plexus, circular muscle plexus or tertiary plexus in 4 out of 4 preparations cultured 
in any of the four conditions (Figures 7-10) using the Syn-O1 antiserum. In addition, labeling 
of oligomers was not detected in any myenteric nerve cell bodies under any of the conditions 
tested (Figures 3-10).  
 
Autofluorescent cell bodies in the myenteric plexus during organotypic culture 
 
Faintly autofluorescent nerve cell bodies could be detected in some preparations that had been 
maintained in organ culture, but not in fresh-fixed preparations. They were visible in all filter 
sets (Cy3, Cy5, FITC and AMCA), but most readily identified in the FITC filter set (Figure 
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11). In unlabeled preparations, cultured under the four different conditions for 1-4 days, a 
blinded observer randomly selected 20 myenteric ganglia and quantified autofluorescent cell 
bodies. The highest number was counted in tissue exposed to 10μM rotenone after 4 days of 
culture (Table 5), with similar proportions identified in specimens cultured for 2 and 4 days 
with 1μM rotenone (Table 5). Autofluorescent cell bodies were clustered in ganglia, with 
some ganglia containing none, and others containing 10 or more. Autofluorescent cell bodies 
were too infrequent to count accurately in preparations cultured in standard DME/F12 
medium or in medium containing 10mM KCl (see Table 5), but small numbers were present 
when actively sought out, which could be targeted for subsequent immunohistochemical 
labeling – see below (Table 6).  
 
Neurochemical coding of autofluorescent cell bodies after organotypic culture 
 
In the present study, preparations labeled with antisera against NOS and ChAT were 
subsequently visualised with secondary antibodies conjugated to Cy3 and Cy5, respectively. 
As described in the methods section, autofluorescent nerve cell bodies were clearly visible in 
using FITC filters (Figure 11) and in unstained preparations in Cy3 and Cy5 filters. However, 
the autofluorescent signal did not appear to break through into Cy3 and Cy5 channels after 
NOS and ChAT immunolabeling, presumably because the dim autofluorescent signal was 
overwhelmed by the background NOS or ChAT immunofluorescence. This allowed us to 
identify whether autofluorescent nerve cell bodies were immunoreactive for ChAT and/or 
NOS (Table 6). In all preparations analysed, autofluorescent cell bodies were either 
ChAT+/NOS- or ChAT-/NOS- (Table 6). ChAT+/NOS- cells were more abundant than 
ChAT-/NOS- cells (P = 0.0472, Table 6). We also compared the proportions of 
ChAT+/NOS- and ChAT-/NOS- cell bodies after organ culture after 1-4 days in the four 
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different solutions (Table 7). In the tissue cultured with 1μM or 10μM rotenone (Figures 12 
and 13), after 1, 2 or 4 days of culture the majority of autofluorescent cell bodies were 
ChAT+/NOS-, with a small proportion being ChAT-/NOS- (Table 7). No NOS-IR neurons 
were autofluorescent.  
 
DISCUSSION 
 
α-Synuclein is a neuronal protein localized to presynaptic terminals that normally exists as an 
unfolded, aggregation-prone, monomer or as a stable, aggregation-resistant, tetramer with a 
rich α-helix conformation (34). These tetramers differ from the pathological oligomers that 
serve as intermediates to the α-synuclein fibrils that are the major component of Lewy 
pathology, which vary in size and have a β-sheet conformation (35). A variety of α-synuclein 
species have been identified in Lewy pathology, including truncated fragments those modified 
by oxidation, nitration, phosphorylation and ubiquitylation, and those having undergone 
various stages of aggregation (36). Thus, there may be multiple intermediates in the formation 
of mature synuclein fibrils. Conventional α-synuclein antibodies do not distinguish α-
synuclein species; therefore, conformation-specific antibodies are required to detect specific 
pathological features of Parkinson’s disease.  
 
In this study, we used three α-synuclein antisera to detect changes in α-synuclein expression 
in enteric neurons following rotenone exposure or raised KCl concentration in ex vivo 
segments of guinea-pig ileum. Our conventional α-synuclein antibody that detects monomers, 
oligomers and fibrils did not detect any morphological abnormalities in α-synuclein form or 
distribution caused by rotenone or KCl. In contrast, the conformation-specific Syn-F2 showed 
increased expression of α-synuclein fibrils in axons of enteric neurons after rotenone and KCl 
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treatment. Rotenone also increased the number of autofluorescent cell bodies in myenteric 
ganglia. The majority of these was immunoreactive for choline acetyltransferase: none was 
immunoreactive for nitric oxide synthase. This suggests that nitrergic enteric neurons may be 
selectively less sensitive to rotenone exposure than cholinergic neurons. Notably, nitrergic 
enteric neurons do not express α-synuclein, whereas nearly all cholinergic neurons do (1). The 
effects of KCl may be mediated by increased neural excitability and we speculate that this 
may increase expression of α-synuclein fibrils, although the mechanism is far from clear. 
 
Accumulation of α-synuclein in enteric neurons after organotypic culture  
 
Pathological α-synuclein species have recently been reported in the gastrointestinal tract of 
patients with Parkinson’s disease, but not in age-matched healthy controls (37, 38). However, 
“pathological” α-synuclein species have been detected in the gut of healthy asymptomatic 
ageing adults (39, 40, 41, 42). Early studies of the GI tract in Parkinson’s disease reported 
Lewy bodies and neurites comparable to those observed in brain (43, 44, 45). Animal studies 
have reported morphological changes in α-synuclein localisation in the enteric nervous system 
of mice expressing SNCA mutants associated with Parkinson’s disease (46, 47, 48), and after 
exposure to rotenone (49, 50), and MPTP (51). In this study, we observed an increase in 
presence of abnormally large axonal varicosities containing α-synuclein, after one or more 
days in organ culture, with or without raised KCl or rotenone. Whether these swollen 
varicosities were a consequence of α-synuclein accumulation in terminals, decreased 
clearance, or accumulation of pathological species is not clear. They were unlikely to be 
axotomy-induced degeneration, since they were not identified in a previous ultrastructural 
comparison of fresh and cultured tissue (52). Effects of rotenone on the enteric nervous 
system may depend on species and region of gut, concentration and exposure to rotenone and 
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recovery time. Thus, Greene et al., 2009 noted no change in α-synuclein expression in the 
ileum and proximal colon (53), but an increase was seen in the jejunum (49), duodenum and 
ileum (54). Another study reported an initial decrease, followed at 6 months by an increase in 
α-synuclein (50). The present study used concentrations of rotenone and durations of 
exposure reported to cause α-synuclein accumulation and nerve cell death in brain slices (55, 
56), albeit higher than required to cause the first signs of nigrostriatal degeneration (57).   
 
Rotenone and raised KCl concentration cause accumulation of α-synuclein fibrils  
 
α-Synuclein fibrils are the major component of Lewy bodies and neurites (2, 3, 4). SNCA 
missense mutations underlie some cases of Parkinson’s disease and accelerate formation of α-
synuclein oligomers and fibrils  (58, 59), which are toxic (60, 61), causing synaptic and nerve 
cell degeneration, and seeding aggregation of endogenous α-synuclein in central and 
peripheral nerve cells (20, 21). Here, we observed accumulation of α-synuclein fibrils in the 
axons, but not cell bodies, of cholinergic interneurons and motorneurons in the guinea-pig 
ileum after exposure to rotenone in a concentration- and time-dependent manner. Raising KCl 
concentration in medium for 1-4 days also caused accumulation of α-synuclein fibrils in these 
same axons, but not cell bodies.  
This occurred despite no detectable overall morphological changes in α-synuclein detected by 
conventional antiserum. No accumulation of α-synuclein oligomers was detected with a 
conformation-specific antiserum under the same conditions. The Syn-F2 and Syn-O1 
antibodies do not recognize the same epitopes (30). The Syn-F2 antibody preferentially binds 
more mature synuclein fibrils, whilst Syn-O1 antibody recognizes both early α-synuclein 
oligomers as well as late synuclein fibrils (30).  
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The mechanisms of how raised [K+] and rotenone cause fibril formation were not 
investigated. However, production of α-synuclein fibrils may be related to its role in the 
synaptic vesicle cycle. Neurotransmitter release requires assembly of SNARE complexes that 
facilitate fusion pore formation (62). SNARE complex assembly and disassembly occurs 
repeatedly during periods of fast action potential firing, often at considerable distances from 
the nerve cell body. SNARE proteins form highly reactive intermediates that can misfold and 
aggregate (63, 64). α-Synuclein appears to function as a molecular chaperone of the v-
SNARE, synaptobrevin-2, limiting its misfolding and aggregation (63). It may become a 
victim of bystander damage inflicted by such reactive intermediates, leading to dissociation of 
the stable tetrameric form (65) intro unstable monomers. If protective mechanisms are 
overwhelmed during periods of prolonged high frequency firing, perhaps due to ATP 
depletion driven by demands of the Na+/K+ ATPase, this could explain the effects of raised 
[K+] in vitro on fibril formation.    
 
Rotenone causes necrosis of cholinergic enteric neurons 
 
Exposure to rotenone evoked autofluorescence in many nerve cell bodies, consistent with 
ongoing necrosis (66, 67, 68, 69). Over 80% of these cell bodies were immunoreactive for the 
cholinergic marker, ChAT. The remainder lacked both ChAT and NOS immunoreactivity. 
Cholinergic neurons comprise from 68-81% of myenteric neurons in guinea pig small 
intestine (70; 71) and α-synuclein is restricted to cholinergic neurons in this same preparation 
(1). What is most striking about these figures is that none of the autofluorescent cells was 
immunoreactive for nitric oxide synthase, despite NOS being present in 20-25% of myenteric 
neurons in guinea pig ileum (72). This either suggests that NOS-containing neurons are 
resistant to rotenone-induced necrosis, or that NOS immunoreactivity is lost from necrotic 
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nerve cells. If rotenone’s toxicity is mediated through aggregation of α-synuclein, then this 
may explain the selective loss of cholinergic neurons in our preparation, as nitrergic neurons 
do not express α-synuclein (1, 32). Nitric oxide synthase may have a neuroprotective effect on 
enteric neurons in inflammation (73) and ischemia/reperfusion (74). Reactive oxygen species 
are produced in ischemia/reperfusion (75); it is possible that NOS-containing neurons have 
higher levels of endogenous antioxidants to cope with reactive oxygen species during nitric 
oxide synthesis.  
 
α-Synuclein as a biomarker and therapeutic target in the GI tract 
 
Using a threshold dilution, we achieved selective immunolabeling for α-synuclein fibrils in 
the enteric nervous system. Potentially, this may be a simple way of determining whether 
pathological α-synuclein species are elevated in Parkinson’s disease. α-Synuclein accumulates 
in the gut in the preclinical stage of Parkinson’s disease, it is possible that conformation-
specific antibodies to α-synuclein fibrils may be useful in early diagnosis based on colonic 
biopsies.  
 
In conclusion, rotenone exposure and prolonged raised [K+] caused accumulation of α-
synuclein fibrils in the axons of cholinergic enteric neurons. This took place in a time- and, in 
the case of rotenone, concentration-dependent manner. Rotenone also caused selective 
necrosis of cholinergic enteric neurons in a concentration-dependent manner. Conformation-
specific antibodies to α-synuclein may be valuable tools for assessment of pathological 
features in the enteric nervous system. 
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Primary 
Antibody 
Immunising antigen Manufacturer, 
catalogue #, lot # 
Dilution Raised 
α-Synuclein Human α -synuclein residue 
116-131 (peptide sequence:
MPVDPDNEAYEMPSEEC)
Gai et al., (1999) 1:1000 Sheep 
Syn-F2 α-synuclein fibrils Vaikath et al., 
(2015) 
1:200 Mouse 
Syn-O1 α-synuclein fibrils Vaikath et al., 
(2015) 
1:1500 Mouse 
ChAT Peptide fragment of purified 
porcine ChAT (GLFSSYR 
LPGHTQDTLVAQKSS) 22 
amino acids: 168-189 
Schemann/P3YEB 1:500 Rabbit 
NOS Recombinant rat neuronal 
NOS 
Emson/K205 1:1000 Sheep 
Table 1. Primary antisera used in the study 
Secondary 
Antibody 
Manufacturer and 
catalogue # 
Dilution Raised Conjugated 
fluorophore 
Donkey anti-
sheep IgG 
Jackson, 71 165 147 1:200 Donkey Cy3 
Donkey anti-
rabbit IgG 
Jackson, 711 175 152 1:200 Donkey Cy5 
Donkey anti-
mouse IgG 
Jackson, 715 165 151 1:200 Donkey Cy3 
Table 2. Secondary antisera used in the study 
Normal varicosities Abnormally large 
varicosities 
Mean area ± SEM 0.21 ± 0.0 μm
2
1.39 ± 0.1 μm
2
n=4 
Table 3. Mean area of normal and abnormally large a-synuclein varicosities in the tertiary 
plexus after various conditions of culture of different duration  
Fresh fixed 
tissue (Mean 
± SEM, 
range)  
Standard 
medium (Mean 
± SEM, range) 
1μm rotenone 
(Mean ± SEM, 
range) 
10μm rotenone 
(Mean ± SEM, 
range) 
10mM KCl 
(Mean ± SEM, 
range) 
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Day 1 0 ± 0 (0-0) 4 ± 4 (0-14) 12 ± 7 (1-28) 5 ± 2 (2-5) 17 ± 9 (2-7) 
Day 2 0 ± 0 (0-0) 34 ± 18 (5-39) 47 ± 22 (10-65) 17 ± 6 (7-27) 17 ± 9 (0-37) 
Day 4 0 ± 0 (0-0) 18 ± 13 (1-27) 21 ± 14 (4-53) 52 ± 28 (3-87) 17 ± 11 (8-22) 
n=4 
Table 4. Mean proportion of abnormally large varicosities containing α-synuclein in the 
tertiary plexus  
Control 
(Mean ± SEM, 
range # cells) 
10mM KCl 
(Mean ± SEM, 
range # cells) 
1μm rotenone 
(Mean ± SEM, 
range # cells) 
10μm rotenone 
(Mean ± SEM, 
range # cells) 
Day 1 0 ± 0 0 ± 0 0 ± 0 14 ± 8 (0-20) 
Day 2 0 ± 0 0 ± 0 34 ± 11 (0-27) 16 ± 15 (0-11) 
Day 4 0 ± 0 0 ± 0 33 ± 17 (0-20) 50 ± 29 (3-60) 
n=4 
Table 5. Mean proportion of autofluorescent cell bodies in the myenteric plexus after the four 
conditions of culture of 1-4 days duration 
ChAT+/NOS- ChAT-/NOS- 
Mean ± SEM, range 74 ± 22 (17-121) 18 ± 3.4 (8-24) 
n = 4 
Table 6. Mean number of nerve cell bodies that were ChAT+/NOS- or ChAT-/NOS- after 
pooling all autofluorescent cell bodies sampled after the four conditions of culture of 1-4 days 
duration 
Control 
(Mean ± SEM, 
range # cells) 
10mM KCl 
(Mean ± SEM, 
range # cells) 
1μm rotenone 
(Mean ± SEM, 
range # cells) 
10μm rotenone 
(Mean ± SEM, 
range # cells) 
ChAT+/
NOS- 
ChAT-
/NOS- 
ChAT+/
NOS- 
ChAT-
/NOS- 
ChAT+/
NOS- 
ChAT/N
OS- 
ChAT+/
NOS- 
ChAT-
/NOS- 
Day 1 6 ± 6 
(0-6) 
0 ± 0 30 ± 23.9 
(0-27) 
8 ± 8 
(0-9) 
27 ± 17 
(0-13) 
0 ± 0 34 ± 22 
(3-27) 
13 ± 9 
(0-5) 
Day 2 8 ± 9 
(0-9) 
0 ± 0 9 ± 6 
(0-6) 
15 ± 15 
(0-8) 
32 ± 13 
(0-16) 
6 ± 4 
(0-4) 
47 ± 21 
(0-14) 
14 ± 9 
(0-5) 
Day 4 15 ± 7 
(0-8) 
13 ± 7 
(0-7) 
14 ± 9 
(0-10) 
6 ± 4 
(0-4) 
27 ± 17 
(0-19) 
11 ± 5 
(0-4) 
38 ± 23 
(0-32) 
1 ± 1 
(0-1) 
n=4 
Table 7. Mean proportion of ChAT+/NOS- and ChAT-/NOS- autofluorescent cell bodies in 
the myenteric plexus after the four conditions of culture of 1-4 days duration 















